Posaconazole in intensive care patients I: Invasive fungal infections in surgical intensive care and case presentation

Mycoses

Volumn 51, Issue SUPPL. 2, 2008, Pages 52-57

  Störzinger, Dominic ^a,b   Lichtenstern, Christoph ^a   Swoboda, Stefanie ^a   Weigand, Markus A ^a   Hoppe Tichy, Torsten ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Antifungal; Aspergillosis; Candidiasis; Gavage; Immunodeficiency; Infection; Invasive fungal infection; Posaconazole

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; TACROLIMUS; VORICONAZOLE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIBIOTIC THERAPY; APACHE; ARTERY CATHETERIZATION; ARTICLE; ARTIFICIAL VENTILATION; ASPERGILLOSIS; ASPERGILLUS; BLADDER CATHETERIZATION; CANDIDA ALBICANS; CANDIDEMIA; CASE REPORT; CRITICALLY ILL PATIENT; DIALYSIS; DIGESTIVE SYSTEM PERFORATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG TOLERABILITY; FEEDING; FEVER; FUNGAL COLONIZATION; GASTROINTESTINAL SURGERY; HUMAN; HYPOKALEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INJURY; INTENSIVE CARE UNIT; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LENGTH OF STAY; LIVER FAILURE; LIVER TOXICITY; NEPHROTOXICITY; OROPHARYNX CANDIDIASIS; PARENTERAL NUTRITION; PRIORITY JOURNAL; STRESS ULCER; SURGICAL PATIENT; VANCOMYCIN RESISTANT ENTEROCOCCUS; VEIN CATHETERIZATION;

AGED; ANTIBIOTICS, ANTIFUNGAL; ASPERGILLOSIS; CANDIDIASIS; CROSS INFECTION; HUMANS; INTENSIVE CARE; MIDDLE AGED; MYCOSES; POSTOPERATIVE COMPLICATIONS; TRIAZOLES;

ASPERGILLUS; CANDIDA; FUNGI;

EID: 47949084565     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2008.01573.x     Document Type: Article

References (35)

1. Lichtenstern C, Schmidt J, Knaebel HP, Martin E, Büchler MW, Weigand MA. Postoperative bacterial/fungal infections: a challenging problem in critically ill patients after abdominal surgery. Dig Surg 2007 24 : 1 11.
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003 348 : 1546 54.
3. Vincent JL, Sakr Y, Sprung CL et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006 34 : 344 53.
4. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005 18 : 44 69.
5. Vincent JL, Anaissie E, Bruining H et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intens Care Med 1998 24 : 206 16.
6. Blumberg HM, Jarvis WR, Soucie JM et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001 33 : 177 86.
7. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992 326 : 845 51.
8. Petri MG, Konig J, Moecke HP et al. Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich Society for Chemotherapy, Divisions of Mycology and Pneumonia Research. Intens Care Med 1997 23 : 317 25.
9. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002 347 : 2020 9.
10. Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007 45 : 205 16.
11. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine 1999 78 : 123 38.
12. Solomkin JS, Mazuski JE, Baron EJ et al. Guidelines for the selection of anti-infective agents for complicated intraabdominal infections. Clin Infect Dis 2003 37 : 997 1005.
13. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006 173 : 707 17.
14. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet 2005 366 : 1013 25.
15. Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007 44 : 2 12.
16. Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003 47 : 2788 95.
17. Courtney R, Radwanski E, Lim J, Laughlin M. Pharmacokinetics of posaconazole coadmnistered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004 48 : 804 8.
18. Sansone A, Belle D, Statkevich P et al. Effect of posaconazole on the pharmacokinetics of tacrolimus in healthy volunteers. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, 2003 : September 14-17 (Abstract A-1603).
19. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharmaceut Sci 2004 21 : 645 53.
20. NOXAFIL. Fachinformation, SP Europe (dated October 2006).
21. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. New Engl J Med 2007 356 : 335 47.
22. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007 356 : 348 59.
23. Kullberg BJ, Sobel JD, Ruhnke M et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005 366 : 1435 42.
24. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med 2006 34 : 857 63.
25. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007 356 : 2472 82.
26. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007 369 : 1519 27.
27. Stevens DA, Kan VL, Judson MA et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000 30 : 696 709.
28. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002 347 : 408 15.
29. Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003 36 : 1122 31.
30. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004 39 : 1563 71.
31. Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med 2005 33 : 1928 35.
32. Pelz RK, Hendrix CW, Swoboda SM et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001 233 : 542 8.
33. Magill SS, Shields C, Sears CL, Choti M, Merz WG. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006 44 : 529 35.
34. Marik PE. Fungal infections in solid organ transplantation. Expert Opin Pharmacother 2006 7 : 297 305.
35. Vincent JL, Bihari DJ, Suter PM et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995 274 : 639 44.